ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 64 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $10,358,000 | -12.5% | 433,585 | 0.0% | 0.46% | -9.2% |
| Q2 2021 | $11,833,000 | -45.1% | 433,585 | -41.8% | 0.51% | -32.4% |
| Q1 2021 | $21,535,000 | -11.7% | 744,370 | -14.2% | 0.76% | -30.5% |
| Q4 2020 | $24,393,000 | -25.2% | 867,170 | -22.1% | 1.09% | -42.2% |
| Q3 2020 | $32,619,000 | -16.3% | 1,113,265 | -13.7% | 1.88% | -32.6% |
| Q2 2020 | $38,990,000 | -22.4% | 1,289,360 | -23.5% | 2.80% | -38.6% |
| Q1 2020 | $50,259,000 | – | 1,686,527 | – | 4.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |